2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Apoptosis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Study Population, Human, Adult, Animal Model
PAPER

5007 Hyperactivation of the mitochondrial protease, ClpP, depletes the helicase, SUV3, promotes the accumulation of double-stranded RNA, increases interferon signalling, and sensitizes AML cells to immune-mediated killing

Taylor Barbieri, Saurabh Kumar Kumar Gupta, Postdoctoral Fellow2, Rose Hurren3, Geethu Emily Thomas, PhD, MSc, BSc4, Marcela Gronda5, Yulia Jitkova6, Karen Fang, MS7, Leah Hui-Ching Tang8, Veronique Voisin, PhD9, Nathan Duong, BSc10, Ali Chegini, MSc11, Anastasija Piric12, Andrea Arruda13, Maria Perusini, MD, Msc14, Li Zhang, MD, PhD15, Carman K. M. Ip16, Troy Ketela17, Kazuharu Kamachi, MD, PhD18, Liang Zhang, PhD19, Ran Zhao, MSc20, Li Li, MD, PhD21, Silvia Tiberti22, Byron Jia23, Katayoun Rezvani, MD, PhD24, May Daher, MD, MD25, Michael Andreeff, MD, PhD26, Jo Ishizawa, MD, PhD27, Aaron Schimmer, MD PhD28
1 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
4 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
5 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
6 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
7 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
8 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
9 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
10 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
11 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
12 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
13 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
14 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
15 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
16 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
17 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
22 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
23 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
24 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
25 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
26 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
27 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
28 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Mitochondria generate energy through oxidative phosphorylation and contain their own genome and machinery for DNA replication and transcription. Their unique bidirectional transcription produces double-stranded RNA (dsRNA) as a byproduct. This dsRNA is a mitochondrial stress signal that controls nuclear gene expression, stemness, and immune responsiveness. As such, it represents an important biological pathway connecting the mitochondria to the nuclear genome as well as a novel therapeutic vulnerability for acute myeloid leukemia (AML), a disease with increased rates of mitochondrial transcription. To identify compounds that promote accumulation of mitochondrial dsRNA in AML, we conducted a targeted drug screen of mitochondrial active agents and identified dordaviprone (ONC201), a small-molecule activator of the mitochondrial protease ClpP recently approved for the treatment of brain tumors and under clinical investigation in AML. We confirmed that dordaviprone promoted dose- and time-dependent dsRNA accumulation in AML cell lines (n = 4) – resulting in a 3- to 8-fold increase in dsRNA-positive cells compared to DMSO controls – which preceded the onset of cell death.

The accumulation of dsRNA can activate the interferon signaling pathway. We demonstrated that dordaviprone increased interferon signaling with 3.0-, 3.0-, and 2.5-fold increases in IFNγR1, IFNγ, and STAT1 expression, respectively, by RT-qPCR. Co-treatment with the TBK1 inhibitor, GSK8612, prevented this increase, demonstrating dependency on dsRNA-mediated RIG1/TBK1 signaling.

We also demonstrated that an increase in dsRNA and interferon signaling induced by dordaviprone was dependent on hyperactivation of the mitochondrial protease ClpP. Cells with ClpP loss-of-function mutations or treatment with an inactive ONC201 isomer abrogated dsRNA accumulation and the associated interferon response, indicating that the observed phenotype with dordaviprone was dependent on activating ClpP.

To further dissect this mechanism, BioID mass spectrometry identified the mitochondrial helicase, SUV3, which mediates mitochondrial dsRNA degradation, as a putative substrate of hyperactivated ClpP. We confirmed that SUV3 is a ClpP substrate and hyperactivation of ClpP with dordaviprone reduced intracellular levels of SUV3.

We next asked whether ClpP-induced viral mimicry translates into enhanced immune-mediated leukemia cell killing. Consistently, dordaviprone sensitized AML cells to immune-mediated cytotoxicity by NK92 cells, CD70-CAR-NK, and CD123-CAR-T cells (p<0.001). Importantly, direct exposure of NK or T cells to dordaviprone did not impair their viability or function. Notably, pretreatment of NK cells with dordaviprone did not enhance their antitumor activity, whereas pretreatment of AML cells markedly increased NK cell-mediated AML killing (p<0.0001), indicating that enhanced cytotoxicity was driven by leukemia cell-intrinsic immune activation. Furthermore, combining dordaviprone and venetoclax with NK cells or CD123-CAR-T cells induced greater AML cell killing than either agent alone or dual combination (p<0.001).

Thus, in summary, we discovered that the mitochondrial protease ClpP regulates mitochondrial stress pathways by controlling the levels of SUV3 and the subsequent accumulation of mitochondrial dsRNA, thereby activating antileukemia immunity. Hyperactivation of ClpP with the clinically approved drug dordaviprone can thus be a novel therapeutic approach to sensitize AML cells to immune-mediated killing.
Taylor Barbieri: No relevant conflicts of interest to declare.